Answers are grounded in this paper and cite their sources.
Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Early studies indicate that it will play a big role in AML treatment. This is a short review about this drug.
No takes yet. Share an insight, caveat, or question.
Lalit Raut (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: